Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00075855 · ClinicalTrials.gov registry record · Phase 3

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
150
Enrollment target

NCT00075855 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00075855, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
150 participants
Enrollment target

Study Summary

RATIONALE: The hormone testosterone may improve the libido (sex drive) in women. It is not yet known whether testosterone is effective in improving libido in female cancer survivors. PURPOSE: This randomized phase III trial is studying how well low-dose testosterone works to improve libido in postmenopausal cancer survivors.

Interventions

  • OTHER placebo
  • DRUG therapeutic testosterone

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2004-04
Est. Completion 2007-10
Phase Phase 3

What the Registry Record Tells You About NCT00075855

The ClinicalTrials.gov registry entry for NCT00075855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT00075855 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00075855 about?

NCT00075855 is a clinical study titled "Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors". RATIONALE: The hormone testosterone may improve the libido (sex drive) in women. It is not yet known whether testosterone is effective in improving libido in female cancer survivors. PURPOSE: This randomized phase III trial is studying how well low-dose testosterone works to improve libido in postm...

What is the current status of trial NCT00075855?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2004-04. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00075855?

The interventions under investigation include: placebo (OTHER), therapeutic testosterone (DRUG).

Who is sponsoring clinical trial NCT00075855?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.